Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

about

Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physicians

P2860

Q58783217-B2E9ABA5-B257-4526-BB30-D5965649ABE5

P2860

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

Item

http://www.wikidata.org/entity/Q40362543

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Enhancing accrual to chemother ...... ey of physicians and patients.

@en

type

Item

label

Enhancing accrual to chemother ...... ey of physicians and patients.

@en

prefLabel

Enhancing accrual to chemother ...... ey of physicians and patients.

@en

P1476

Enhancing accrual to chemother ...... vey of physicians and patients

@en

P2093

Anil A Joy

http://www.w3.org/2001/XMLSchema#string

Carmel Jacobs

http://www.w3.org/2001/XMLSchema#string

John Hilton

http://www.w3.org/2001/XMLSchema#string

Lisa Vandermeer

http://www.w3.org/2001/XMLSchema#string

Mark Clemons

http://www.w3.org/2001/XMLSchema#string

Mohammed Ibrahim

http://www.w3.org/2001/XMLSchema#string

Muriel Brackstone

http://www.w3.org/2001/XMLSchema#string

Orit Freedman

http://www.w3.org/2001/XMLSchema#string

P2860

The epidemiology of triple-negative breast cancer, including race

Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.

P2888

s00520-017-3580-4

P304

1881-1886

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-017-3580-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Brian Hutton

Dean A Fergusson

Sasha Mazzarello

P577

2017-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1074228344

http://www.w3.org/2001/XMLSchema#string

P698

28127659

http://www.w3.org/2001/XMLSchema#string

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

about

P2860

P2860

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698